These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24900747)

  • 21. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
    Brown SP; Dransfield PJ; Vimolratana M; Jiao X; Zhu L; Pattaropong V; Sun Y; Liu J; Luo J; Zhang J; Wong S; Zhuang R; Guo Q; Li F; Medina JC; Swaminath G; Lin DC; Houze JB
    ACS Med Chem Lett; 2012 Sep; 3(9):726-30. PubMed ID: 24900539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
    Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
    Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
    Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights into unbound-bound states of GPR142 receptor in a membrane-aqueous system using molecular dynamics simulations.
    Kaushik AC; Sahi S
    J Biomol Struct Dyn; 2018 May; 36(7):1788-1805. PubMed ID: 28571491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.
    McKillop AM; Moran BM; Abdel-Wahab YH; Gormley NM; Flatt PR
    Diabetologia; 2016 Dec; 59(12):2674-2685. PubMed ID: 27677765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.
    McKillop AM; Moran BM; Abdel-Wahab YH; Flatt PR
    Br J Pharmacol; 2013 Nov; 170(5):978-90. PubMed ID: 23992544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Kimura T; Toda N
    Bioorg Med Chem; 2015 Sep; 23(17):5546-65. PubMed ID: 26234904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigational insulin secretagogues for type 2 diabetes.
    Scheen AJ
    Expert Opin Investig Drugs; 2016; 25(4):405-22. PubMed ID: 26881467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AWRK6, a Novel GLP-1 Receptor Agonist, Attenuates Diabetes by Stimulating Insulin Secretion.
    Wang Q; Zhao C; Jin L; Zhang H; Miao Q; Liu H; Zhang D
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
    Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
    Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.
    Brown SP; Dransfield P; Vimolratana M; Zhu L; Luo J; Zhang J; Jiao X; Pattaropong V; Wong S; Zhuang R; Swaminath G; Houze JB; Lin DC
    ACS Med Chem Lett; 2018 Jul; 9(7):757-760. PubMed ID: 30034614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
    Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice.
    Oshima H; Yoshida S; Ohishi T; Matsui T; Tanaka H; Yonetoku Y; Shibasaki M; Uchiyama Y
    Life Sci; 2013 Feb; 92(2):167-73. PubMed ID: 23246743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agen.
    Sugawara K; Honda K; Reien Y; Yokoi N; Seki C; Takahashi H; Minami K; Mori I; Matsumoto A; Nakaya H; Seino S
    PLoS One; 2016; 11(10):e0164785. PubMed ID: 27764176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
    Luo J; Nguyen K; Chen M; Tran T; Hao J; Tian B; Rulifson IC; Zhang Y; Tian L; Zhang Y; Lopez E; Lin DC; Wang Y; Ma Z; Houze J; Guo Z
    Metabolism; 2013 Jan; 62(1):90-9. PubMed ID: 22982177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.